Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab

• Published in: BMC cancer Vol. 19; no. 1; p. 974
• Main Authors: Masuda, Ken, Shoji, Hirokazu, Nagashima, Kengo, Yamamoto, Shun, Ishikawa, Masashi, Imazeki, Hiroshi, Aoki, Masahiko, Miyamoto, Takahiro, Hirano, Hidekazu, Honma, Yoshitaka, Iwasa, Satoru, Okita, Natsuko, Takashima, Atsuo, Kato, Ken, Boku, Narikazu
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 21.10.2019; BioMed Central; BMC
• Subjects: Adrenal Insufficiency - etiology; Adult; Adverse drug reactions; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological - adverse effects; Antineoplastic Agents, Immunological - pharmacology; Antineoplastic Agents, Immunological - therapeutic use; Aspartate; Cancer; Cancer metastasis; Cancer patients; Care and treatment; Cell death; Development and progression; Diarrhea - etiology; Female; Follow-Up Studies; Gastric cancer; Humans; Hyperglycemia; Hyperglycemia - etiology; Immune-related adverse events; Immunotherapy; Immunotherapy - adverse effects; Lung cancer; Male; Medical research; Melanoma; Middle Aged; Nivolumab; Nivolumab - adverse effects; Nivolumab - pharmacology; Nivolumab - therapeutic use; Patient outcomes; Prognosis; Programmed Cell Death 1 Receptor - antagonists & inhibitors; Programmed cell death-1; Progression-Free Survival; Retrospective Studies; Risk factors; Stomach cancer; Stomach Neoplasms - drug therapy; Stomach Neoplasms - mortality; Survival Rate; Immune-related adverse events; Programmed cell death-1; Gastric cancer; Nivolumab
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-019-6150-y

Recent studies have shown that immune-related adverse events (irAEs) caused by immune checkpoint inhibitors were associated with clinical benefit in patients with melanoma or lung cancer. In advanced gastric cancer (AGC) patients, there have been few reports about the correlation between irAEs and efficacy of immune checkpoint inhibitors. In this study, we retrospectively investigated the correlation between irAEs and efficacy in AGC patients treated with nivolumab. The subjects of this study were AGC patients received nivolumab monotherapy between January 2015 and August 2018. IrAEs were defined as those AEs having a potential immunological basis that required close follow-up, or immunosuppressive therapy and/or endocrine therapy. We divided the patients who received nivolumab into two groups based on occurrence of irAEs; those with irAEs (irAE group) or those without (non-irAE group). We assessed the efficacy in both groups. Of the 65 AGC patients that received nivolumab monotherapy, 14 developed irAEs. The median time to onset of irAEs was 30.5 days (range 3-407 days). Median follow-up period for survivors was 32 months (95% CI, 10.8 to 34.5). The median progression-free survival was 7.5 months (95% CI, 3.6 to 11.5) in the irAE group and 1.4 months (95% CI, 1.2 to 1.6) in the non-irAE group (HR = 0.11, p < 0.001). The median overall survival was 16.8 months (95% CI, 4.4 to not reached) in the irAE group and 3.2 months (95% CI, 2.2 to 4.1) in the non-irAE group (HR = 0.17, p < 0.001). Multivariate analysis demonstrated that number of metastatic sites ≥2 (HR = 2.15; 95% CI, 1.02 to 4.54), high ALP level (HR = 2.50; 95% CI, 1.27 to 4.54), and absence of irAEs (HR = 9.54, 95% CI, 3.34 to 27.30 for yes vs. no) were associated with a poor prognosis. The most frequent irAEs was diarrhea/colitis (n = 5). Grade 3 adverse events were observed in 6 patients; hyperglycemia (n = 2), diarrhea/colitis (n = 1), adrenal insufficiency (n = 1), aspartate aminotransferase increased (n = 1), peripheral motor neuropathy (n = 1). There were no grade 4 or 5 adverse events related to nivolumab. Development of irAEs was associated with clinical benefit for AGC patients receiving nivolumab monotherapy.